LUNG CANCER
David R. Gandara, MD
University of California, Davis
    David R. Gandara, MD, is the director of the Thoracic Oncology Program, professor of medicine, and senior adviser to the director at the University of California Davis Comprehensive Cancer Center (UCDCCC).
    • Dr Gandara‚Äôs research interests focus on developmental therapeutics of new anticancer agents as well as preclinical modeling and clinical research in lung cancer.
    • He is the principal investigator on an Early Therapeutics award from the National Cancer Institute (NCI), where he leads an interdisciplinary team of clinical oncologists, pharmacologists, molecular biologists, and statisticians in developing new anticancer agents in a variety of novel drug classes.
    • He leads a multispecialty team at SWOG, an NCI-funded national clinical research organization, in studies related to improving therapies for lung cancer and developing predictive biomarkers of therapeutic efficacy.
    • Dr Gandara is also the principal investigator for a multi-institutional collaboration called iGXT (integrated Genetically-engineered mouse models, patient-derived Xenografts, and Clinical Trials) between the NCI Center for Advanced Preclinical Research and Jackson Laboratory, an NCI-designated basic cancer center. The goal of the iGXT project is to develop better preclinical models to optimize cancer drug development and speed the transition to personalized cancer therapy.
    • He serves as clinical director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant program in lung cancer, and is UCDCCC principal investigator for the Stand Up To Cancer dream team in KRAS-mutated lung cancer.
Program Information:
Nominate
Sponsor
News
Previous Inductees:
2013 | 2014
2015 | 2016
2017 | 2018
Connect: